Esophageal candidiasis as a side effect of inhaled fluticasone propionate dry powder: Recovery by switching over to hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP)

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 5, 2006, Pages 193-197

  Kobayashi, Y ^a   Yasuba, H ^a   Kudou, M ^a   Hamada, K ^a   Kita, H ^a  

^a TAKATSUKI RED CROSS HOSPITAL   (Japan)

Author keywords

Esophageal candidiasis; Fluticasone propionate dry powder; Hydrofluoro alkane 134a beclo methasone dipropionate; Inhaled corticosteroid

Indexed keywords

BECLOMETASONE DIPROPIONATE; FLUTICASONE PROPIONATE; NORFLURANE; PRANLUKAST; SALBUTAMOL; SALMETEROL; THEOPHYLLINE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRY POWDER; ESOPHAGUS CANDIDIASIS; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL ENDOSCOPY; HUMAN; INHALATION SPACER; MALE; PRIMARY PREVENTION;

EID: 33646431138     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44193     Document Type: Article

References (21)

1. Adams N, Bestall JM, Lasserson TJ, Jones PW. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma. Cochrane Database Syst Rev. 2004; 2: 1-59.
2. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987; 136: 225-244.
3. Andersen LI, Frederiksen HJ, Appleyard M. Prevalence of esophageal Candida colonization in a Danish population: special reference to esophageal symptoms, benign esophageal disorders, and pulmonary disease. J Infect Dis. 1992; 165: 389-392.
4. Cortes O, Martinez T, Riquelme R, Garcia G. Esophageal candidiasis in HIV-negative patients. Rev Esp Enf Digest. 1997; 89: 507-510.
5. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ. 2003; 326: 621-625.
6. Fairfax A, Hall I, Spelman R. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. Ann Allergy Asthma Immunol. 2001; 86: 575-582.
7. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995; 98: 196-208.
8. Hoshika K, Mine H. Significance of modes of adherence in esophageal Candida, albicans. J Gastroenterol. 1994; 29: 1-5.
9. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998; 101: S434-439.
10. Kanda N, Yasuba H, Takahashi T, Mizuhara Y, Yamazaki S, Imada Y, Izumi Y, Kobayashi Y, Yamashita K, Kita H, Tamada T, Chiba T. Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate. Am J Gastroenterol. 2003; 98: 2146-2148.
11. Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003; 91: 326-334.
12. Kodsi BE, Wickremesinghe PC, Kozinn PJ, Iswara KW, Goldbeig PK. Candida esophagitis. A prospective study of 27 cases. Gastroenterology. 1976; 71: 715-719.
13. Leach CL, Davidson PJ, Bredow TS, Boudreau RJ. Patient factors influencing the deposition of HFA-beclomethasone dipropionate metered dose inhaler. Eur Respir J. 1998a; 12: 66s.
14. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998b; 12: 1346-1353.
15. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax. 1995; 50: 105-110.
16. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002; 109: 447-460.
17. National Institutes of Health. Global strategy for asthma management and prevention (updated 2002). Bethesda, Maryland: National Institutes of Health; 1995.
18. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004; 126: 213-219.
19. Sievert W, Holmes P, King RW, Oesophageal candidiasis in patients on high-dose inhaled steroids. Lancet. 1992; 339: 1551-1552.
20. Simon MR, Houser WL, Smith KA, Long PM. Esophageal candidiasis as a complication of inhaled corticosteroids. Ann Allergy Asthma Immunol. 1997; 79: 333-338.
21. Yasuba H, Kita H, Kobayashi Y, Yamashita K. Superiority of HFA-BDP, recovery from hoarseness and improvement of small airway function. The Allergy In Practice (Jpn). 2003; 23: 891-897.